• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases.

作者信息

Connolly Caoilfhionn M, Ruddy Jake A, Boyarsky Brian J, Avery Robin K, Werbel William A, Segev Dorry L, Garonzik-Wang Jacqueline, Paik Julie J

机构信息

Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA

Surgery, Johns Hopkins, Baltimore, Maryland, USA.

出版信息

Ann Rheum Dis. 2021 Aug;80(8):1100-1101. doi: 10.1136/annrheumdis-2021-220231. Epub 2021 Mar 19.

DOI:10.1136/annrheumdis-2021-220231
PMID:33741555
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10105326/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46b9/10105326/57d273fbbd48/nihms-1881745-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46b9/10105326/57d273fbbd48/nihms-1881745-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46b9/10105326/57d273fbbd48/nihms-1881745-f0006.jpg

相似文献

1
Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases.mRNA新型冠状病毒2疫苗首剂在风湿性和肌肉骨骼疾病患者中的安全性。
Ann Rheum Dis. 2021 Aug;80(8):1100-1101. doi: 10.1136/annrheumdis-2021-220231. Epub 2021 Mar 19.
2
Safety of third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal disease.风湿性和肌肉骨骼疾病患者接种第三剂严重急性呼吸综合征冠状病毒2疫苗的安全性。
Rheumatology (Oxford). 2022 Oct 6;61(10):e302-e304. doi: 10.1093/rheumatology/keac298.
3
Correspondence on "Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry" by Machado .关于马查多所著的《风湿性和肌肉骨骼疾病患者接种新型冠状病毒疫苗的安全性：欧洲抗风湿病联盟冠状病毒疫苗（COVAX）医生报告登记处的结果》的通信
Ann Rheum Dis. 2023 Dec;82(12):e228. doi: 10.1136/annrheumdis-2022-222118. Epub 2022 Jul 11.
4
Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases.风湿性和肌肉骨骼疾病患者对单剂SARS-CoV-2 mRNA疫苗的抗体反应。
Ann Rheum Dis. 2021 Aug;80(8):1098-1099. doi: 10.1136/annrheumdis-2021-220289. Epub 2021 Mar 23.
5
Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry.接种 SARS-CoV-2 疫苗在风湿免疫疾病患者中的安全性：来自 EULAR 冠状病毒疫苗（COVAX）医生报告登记处的结果。
Ann Rheum Dis. 2022 May;81(5):695-709. doi: 10.1136/annrheumdis-2021-221490. Epub 2021 Dec 31.
6
Spectrum of short-term inflammatory musculoskeletal manifestations after COVID-19 vaccine administration: a report of 66 cases.新型冠状病毒肺炎疫苗接种后短期炎症性肌肉骨骼表现谱：66例报告
Ann Rheum Dis. 2022 Mar;81(3):440-441. doi: 10.1136/annrheumdis-2021-221587. Epub 2021 Nov 26.
7
SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists.风湿性和肌肉骨骼疾病患者对新型冠状病毒2型疫苗的犹豫态度：给风湿病学家的启示
Ann Rheum Dis. 2021 Jul;80(7):953-954. doi: 10.1136/annrheumdis-2021-220059. Epub 2021 Feb 23.
8
Humoral and Cellular Immunogenicity and Safety of Five Different SARS-CoV-2 Vaccines in Patients With Autoimmune Rheumatic and Musculoskeletal Diseases in Remission or With Low Disease Activity and in Healthy Controls: A Single Center Study.五种不同的新型冠状病毒2疫苗在病情缓解或疾病活动度低的自身免疫性风湿和肌肉骨骼疾病患者及健康对照中的体液和细胞免疫原性及安全性：一项单中心研究
Front Immunol. 2022 Mar 31;13:846248. doi: 10.3389/fimmu.2022.846248. eCollection 2022.
9
Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations.风湿与肌肉骨骼疾病患者感染 SARS-CoV-2 及接种 SARS-CoV-2 疫苗的风险和预后：一项系统文献综述，旨在为 EULAR 建议提供信息。
Ann Rheum Dis. 2022 Mar;81(3):422-432. doi: 10.1136/annrheumdis-2021-221575. Epub 2021 Dec 7.
10
Correspondence on 'SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists'.关于“风湿性和肌肉骨骼疾病患者对SARS-CoV-2疫苗的犹豫态度：给风湿病学家的启示”的通信
Ann Rheum Dis. 2021 Oct;80(10):e168. doi: 10.1136/annrheumdis-2021-220586. Epub 2021 May 7.

引用本文的文献

1
Flares of Systemic Autoimmune Rheumatic Disease Following Coronavirus Disease 2019 Vaccination: A Narrative Review.COVID-19 疫苗接种后全身性自身免疫性风湿病的 flares：一项叙述性综述。
Rheum Dis Clin North Am. 2025 Feb;51(1):75-92. doi: 10.1016/j.rdc.2024.08.005. Epub 2024 Oct 15.
2
The effect of COVID-19 vaccination on multiple sclerosis activity as reflected by MRI.COVID-19 疫苗接种对 MRI 反映的多发性硬化症活动的影响。
Brain Behav. 2024 Jul;14(7):e3587. doi: 10.1002/brb3.3587.
3
What is the Safety of COVID-19 Vaccines in Immunocompromised Patients? Results from the European "Covid Vaccine Monitor" Active Surveillance Study.

本文引用的文献

1
Vaccination against COVID-19: Expectations and concerns of patients with autoimmune and rheumatic diseases.2019冠状病毒病疫苗接种：自身免疫性和风湿性疾病患者的期望与担忧
Lancet Rheumatol. 2021 Apr;3(4):e243-e245. doi: 10.1016/S2665-9913(21)00039-4. Epub 2021 Feb 22.
2
Safety of the First Dose of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients.实体器官移植受者中首剂严重急性呼吸综合征冠状病毒2疫苗接种的安全性
Transplantation. 2021 May 1;105(5):e56-e57. doi: 10.1097/TP.0000000000003654.
3
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
免疫功能低下患者接种 COVID-19 疫苗的安全性如何？来自欧洲“Covid 疫苗监测”主动监测研究的结果。
Drug Saf. 2024 Oct;47(10):1011-1023. doi: 10.1007/s40264-024-01449-x. Epub 2024 Jun 22.
4
Clinical disease activity in autoimmune rheumatic patients receiving COVID-19 vaccines.接受新冠病毒疫苗的自身免疫性风湿病患者的临床疾病活动情况。
BMC Rheumatol. 2024 Jun 17;8(1):25. doi: 10.1186/s41927-024-00396-5.
5
COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune rheumatic Diseases (COVIAAD): safety, immunogenicity and antibody persistence at 12 months following Moderna Spikevax primary series.COVID-19 疫苗在自身免疫性风湿病免疫抑制成人中的应用（COVIAAD）：接种 Moderna Spikevax 初级系列后 12 个月的安全性、免疫原性和抗体持久性。
RMD Open. 2023 Nov 29;9(4):e003400. doi: 10.1136/rmdopen-2023-003400.
6
Dermatomyositis Flare-Up Following the SARS-CoV-2 Vaccine: A Case Report and Literature Review.接种新型冠状病毒疫苗后皮肌炎复发：一例报告及文献综述
Cureus. 2023 Aug 29;15(8):e44324. doi: 10.7759/cureus.44324. eCollection 2023 Aug.
7
Immunogenicity and safety of the BBIBP-CorV vaccine in patients with autoimmune inflammatory rheumatic diseases undergoing immunosuppressive therapy in a monocentric cohort.BBIBP-CorV 疫苗在接受免疫抑制治疗的自身免疫性炎症性风湿病患者中的免疫原性和安全性：一项单中心队列研究。
Immun Inflamm Dis. 2023 May;11(5):e858. doi: 10.1002/iid3.858.
8
CVAPPS: A Cross-Sectional Study of SARS-CoV-2 Vaccine Acceptance, Perceptions, and Post-Vaccination Side Effects among Rheumatic Disease Patients in Kuwait.CVAPPS：科威特风湿性疾病患者中SARS-CoV-2疫苗接受度、认知及接种后副作用的横断面研究
Vaccines (Basel). 2023 Mar 15;11(3):666. doi: 10.3390/vaccines11030666.
9
COVID-19 vaccine uptake, hesitancy and clinical effects on patients with Takayasu's arteritis: A web-based questionnaire survey from a large cohort.COVID-19 疫苗接种、犹豫情况及其对大动脉炎患者的临床影响：一项来自大样本的基于网络的问卷调查。
Front Immunol. 2023 Feb 9;14:1030810. doi: 10.3389/fimmu.2023.1030810. eCollection 2023.
10
Immune-Mediated Diseases Following COVID-19 Vaccination: Report of a Teaching Hospital-Based Case-Series.新型冠状病毒肺炎疫苗接种后的免疫介导疾病：基于教学医院的病例系列报告
J Clin Med. 2022 Dec 16;11(24):7484. doi: 10.3390/jcm11247484.
mRNA-1273 新型冠状病毒疫苗的有效性和安全性。
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
4
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
5
Effects of biological and non-biological immunomodulatory therapies on the immunogenicity of vaccines in patients with rheumatic diseases.生物和非生物免疫调节疗法对风湿病患者疫苗免疫原性的影响。
Arthritis Res Ther. 2014 Dec 23;16(6):506. doi: 10.1186/s13075-014-0506-0.